Compare Live Nation Entertainment, Inc. (LYV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Live Nation Entertainment, Inc. trades at $169.98 (market cap $39.33B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Live Nation Entertainment, Inc. is far larger — about 7.8× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is more actively traded (2,060,842 versus 1,350,559). Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LYV | TVTX | |
|---|---|---|
Market Cap | $39.33B | $5.02B |
Volume | 1,350,559 | 2,060,842 |
Sector | Media | Health |
52-Week High | $188.46 | $67.52 |
52-Week Low | $125.61 | $26.79 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $41.54B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $171.32, up 0.99% today, with a neutral technical signal and strong analyst support. The stock shows robust revenue growth, reaching $25.20B in 2025, but profitability remains thin with a net margin of 0.51% and a high P/E of 117.49. Recent news highlights strong fan demand and strategic partnerships, such as the Salesforce integration announced on September 16, 2026, while legal and debt risks persist.
The outlook is cautiously optimistic, driven by sustained demand for live events and a consensus price target of $208.64, but investors face risks from high valuation, regulatory scrutiny, and volatile earnings, with Q3 2026 results critical for confirming growth momentum.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
